Ex Situ Immune Modulation During Lung Transplant
Currently, there is no established standardized protocol for ex-situ immune modulation during ex-vivo lung perfusion (EVLP) for adult lung transplant candidates, as this remains an investigational area without guideline-level recommendations.
Current State of Evidence
The provided guidelines 1 from ISHLT/ATS/ERS (2014) focus exclusively on post-transplant management of bronchiolitis obliterans syndrome and acute rejection—they do not address ex-situ immune modulation during EVLP. These guidelines discuss immunosuppression strategies only after transplantation has occurred.
Emerging Investigational Approaches
While no clinical standard exists, recent research has explored several experimental strategies during EVLP:
Regulatory T Cell (Treg) Administration
The most promising approach involves seeding donor lungs with recipient-derived expanded polyclonal regulatory T cells during EVLP 2. In rat models, pre-transplant Treg administration combined with IL-2/anti-IL-2 antibody complexes and tacrolimus resulted in:
- Increased graft CD25highFoxp3+ content
- Attenuated cellular rejection at 7 days
- Highest Treg-to-effector T cell ratio when combining all three interventions
Critical limitation: Treg therapy alone cannot prevent acute rejection without concurrent systemic immunosuppression 2.
Cytokine Adsorption
Porous polymer bead adsorption devices can reduce inflammatory mediators during EVLP 3. In a human study of 54 EVLP procedures (21 with adsorption, 33 without):
- Significantly decreased IL-6, IL-10, MCP-1, and G-CSF levels
- Lower in-hospital mortality (p = 0.03)
- Reduced 1-year death rate (p = 0.01)
This represents the first human experience suggesting safety and efficacy, though further validation is required 3.
Other Experimental Strategies
- Mesenchymal stem cells (MSC): Investigated for tissue regeneration and immunomodulation during EVLP 4
- Thermal preconditioning: Heat stress at 41.5°C for 30 minutes induces protective heat shock response 5
- Targeted antimicrobial therapy: To reduce infection-related inflammation 6
Clinical Reality Check
The 2024 AATS expert consensus document on donor lung procurement and preservation 7 discusses EVLP extensively but makes no recommendations regarding immune modulation protocols. The focus remains on:
- Assessment using the Toronto, Lund, or OCS protocols
- Evaluation of gas exchange and mechanical parameters
- Biomarker monitoring (IL-6, IL-8, cell-free DNA)
Practical Guidance
Given the absence of established protocols:
Standard EVLP should follow validated protocols (Toronto, Lund, or OCS) without routine immune modulation 7
If considering experimental immune modulation, this should only occur within:
- IRB-approved clinical trials
- Centers with established research protocols
- Appropriate informed consent processes
Post-transplant immunosuppression remains standard: The evidence supports conventional triple-drug immunosuppression initiated at transplantation, not ex-situ modification [1-1]
Important Caveats
- All immune modulation strategies during EVLP remain investigational
- No FDA-approved protocols exist for ex-situ immune therapy
- The field is rapidly evolving with promising preclinical data 2, 3, 4
- Clinical translation requires prospective randomized trials
- Current EVLP use focuses on organ assessment and preservation, not immune manipulation 7, 6, 8
The gap between experimental promise and clinical implementation remains substantial, and routine clinical practice should not incorporate these strategies outside of formal research protocols.